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Abstract: Background: Omics technologies, enabling the measurements of genes (genomics),
mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools
for personalized decision-making. We aimed to identify the existing value assessment frameworks
used by health technology assessment (HTA) doers for the evaluation of omics technologies through a
systematic review. Methods: PubMed, Scopus, Embase and Web of Science databases were searched
to retrieve potential eligible articles published until 31 May 2020 in English. Additionally, through
a desk research in HTA agencies’ repositories, we retrieved the published reports on the practical
use of these frameworks. Results: Twenty-three articles were included in the systematic review.
Twenty-two frameworks, which addressed genetic and/or genomic technologies, were described.
Most of them derived from the ACCE framework and evaluated the domains of analytical validity,
clinical validity and clinical utility. We retrieved forty-five reports, which mainly addressed the
commercial transcriptomic prognostics and next generation sequencing, and evaluated clinical
effectiveness, economic aspects, and description and technical characteristics. Conclusions: A value
assessment framework for the HTA evaluation of omics technologies is not standardized and accepted,
yet. Our work reports that the most evaluated domains are analytical validity, clinical validity and
clinical utility and economic aspects.
Keywords: value assessment frameworks; omics technologies; omics sciences; personalized medicine;
health technology assessment; genomics; proteomics; metabolomics; transcriptomics
1. Introduction
Biological molecules such as DNA, RNA, proteins and metabolites are valuable information
sources to inform clinical decision-making [1]. With the advancement of diagnostic technologies,
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these biological molecules could be exploited in their entirety resulting in the scientific domains:
genomics, transcriptomics, proteomics, and metabolomics [2]. These diagnostic technologies or
“omics” technologies have become readily available in commercial applications [3]. Two prominent
examples in this regard can be considered: Mammaprint and OncotypeDX. These commercial
algorithm-based diagnostic tools examine multiple gene transcripts of a tumor in order to assess
the prognosis of the patient. They rely on “omics” technologies such as next-generation sequencing
and microarray analysis [4,5]. Health technology assessment (HTA) agencies have taken an interest
in these technologies, which already offer a significant value to patients and healthcare systems [6].
In particular, applications of “omic” technologies, as the two commercial diagnostic aiding tools
specified above, have shown to provide prognostic utility to physicians for better therapy selection in
early breast cancer [4,5]. This directly influences patient outcomes and potentially efficient spending
in the healthcare system. Commercial diagnostic tests in other indications, including rheumatoid
arthritis, diabetes, heart transplantation rejection and other cancerous malignancies, have seen their
implementation in the clinic as well. Due to this, the application of these novel “omics” technologies
and their added value have been studied and published by different HTA reports [6]. However,
as promising as these new technologies are, their assessment seemingly proves to be challenging due
to surrounding uncertainty on the clinical utility they provide and their effect on patient outcomes [7].
In addition, from these technologies, a plethora of ethical concerns could arise, which should be
considered during the health technology assessment process [7]. To aid the assessment, the use of
a value assessment framework for the evaluation can provide value to comprehensively map these
issues and identify structural uncertainties to be taken into account.
Value assessment frameworks for diagnostic testing have been developed over the course of
almost three decades, mainly within the field of genetic testing, where information from a single gene is
acquired for diagnostic, prognostic, or predictive purposes. The advancements of “omics” technologies
enable the processing of information on multiple genes, proteins and metabolites, potentially providing
valuable information for clinical decision-making. However, as optimistic as the practice may seem,
a thorough assessment of these technologies is required before being adopted into the healthcare
system, as it should be the case for any technology. The objective of our study was to identify the
existing value assessment frameworks used for the evaluation of the omics-based technologies through
a systematic review of the literature, and to understand their practical use by HTA agencies.
2. Materials and Methods
2.1. Systematic Literature Review on the Value Assessment Frameworks
The systematic review was conducted in accordance with the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) statement [8]. The protocol of this systematic review
was submitted to the International Prospective Register of Systematic Reviews (PROSPERO) and
registered as CRD42020168841.
2.2. Eligibility Criteria
The search question and the eligibility criteria for inclusion in the systematic review were
formulated, addressing the identification of the existing value assessment frameworks used for
the evaluation of omics technologies. To address the research questions in a comprehensive and
appropriate manner, a commonly used definition of omics sciences, omics technologies, HTA and
value assessment frameworks was established. Omics sciences were defined as a set of disciplines
related to molecular biology and biochemistry, through which a holistic knowledge can be achieved,
in analytical terms, of the features and global content of a biological sample. Omics technologies
include genomics, transcriptomics, proteomics and metabolomics. Genomics studies the whole
genome of organisms—their function and structure; transcriptomics—the messenger RNA;
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proteomics—the structure and the functions of the entire proteins; and metabolomics—all chemical
processes involving metabolites in a biological cell, tissue, system or organism [2].
Regarding the HTA definition, we used the health technology assessment international (HTAi)
referred definition, which considers HTA as “a multidisciplinary process that uses explicit methods
to determine the value of a health technology at different points in its lifecycle, aiming to inform
decision-making in order to promote an equitable, efficient, and high-quality health system” [9].
Value assessment frameworks referred to systematic thinking of a health technology assessment,
aiming the collection, evaluation and organization of the evidence at key research questions [10].
Considering the definitions used for the research question, any article or documents that described
a value assessment framework used for the evaluation of omics sciences were considered eligible
for inclusion.
2.3. Search Strategy
The search strategy was performed in PubMed, Scopus, Web of Science and Embase databases in
order to retrieve potential eligible articles published from inception until 31 May 2020.
The search query used in PubMed is:
(Genomic[Title] OR Genomics[Title] OR Proteomic[Title] OR Proteomics[Title] OR Metabolomic[Title]
OR Metabolomics[Title] OR Transcriptomic[Title] OR Transcriptomics[Title] OR Omics[Title] OR Omic[Title])
AND (Assay[Title/Abstract] OR assays[Title/Abstract] OR Test[Title/Abstract] OR Testing[Title/Abstract]
OR Application[Title/Abstract] OR Applications[Title/Abstract]) AND (Assess*[Title/Abstract] OR Evaluat*
[Title/Abstract] OR “Technology Assessment, Biomedical”[Mesh]) AND (Model OR Framework OR Criteria
OR Recommendation*).
In the other databases, we adapted the PubMed query according to the search criteria of each
database. There were no restrictions applied on study design. We restricted the search to only articles
published in the English language, with full-text availability.
2.4. Study Selection and Data Extraction
After searching all the databases, the identified articles were uploaded to Mendeley software and
duplicates were removed. Two independent researchers (LG; IH) performed the first phase of the
screening process, based on titles and abstracts. In the second phase, the selected articles with full text
available were carefully read by two researchers (IH; LG) and then, their reference lists were manually
screened. Articles that satisfied the eligibility criteria were selected for inclusion. All the steps of the
study screening and selection process were reported in a PRISMA flow chart. Any disagreement was
resolved by consensus and discrepancies were discussed with a third researcher (IGI).
Two researchers (IH; LG) independently performed the data extraction from each of the included
articles. A data extraction form (Table 1) was created to retrieve the following data:
- Author, title, year of publication, the name of the journal/website where the framework is published;
- Institution/organization involved in the development of the framework;
- Type of omics technology evaluated (genomics, proteomics, transcriptomics, metabolomics);
- Name of the framework used and name of the reference framework;
- Evaluation components (format, assessment domain);
- Methodology used for the framework development (literature review, Delphi methods, expert
panel, working group consultation).
Int. J. Environ. Res. Public Health 2020, 17, 8001 4 of 21

















2010 EGGAP genomic testing
1. Decision-analytic modeling
2. Health-related utility
3. Risk-benefit policy matrix
To provide a risk-benefit
framework for assessing















-Ethical, legal, and social issues
To develop an assessment
process for genomic testing,
for evaluating, interpreting
















-Analytical validity (analytic sensitivity,
analytic specificity, reliability and assay
robustness);
-Clinical validity (clinical sensitivity and
specificity);
-Clinical utility (effectiveness)
Outline hierarchy of data
sources and study designs













USA N/A 2012 ACCE genomic testing
Phase 1. Initial test performance and
assay refinement;
Phase 2. Test validation and
generalizability;
Phase 3. Clinical test performance and
health impacts;
Phase 4. Comparison with existing tests
Phase 5. Population impacts
To inform where evidence
for a particular diagnostic
or prognostic test is













-Description and technical characteristics;
-Safety;
-Clinical effectiveness;




















USA Not reported 2008 ACCE genomicdiagnostic
12 attributes:
1. Priority for maximizing the health of
individuals or populations;
2. Economic significance of relevant
disease or condition;
3. Genomic diagnostic and drug
combination characteristics;
4. Accuracy of genomic diagnostic;
5. Pertinent sub-groups;
6. Pertinent sub-groups;
7. Reproducibility of diagnostic test;
8. Clinical effectiveness and utility;
9. Presentation of indefinite test results;
10. Regulatory status;
11. Economic analyses
12. Patient outcomes and practicability
To propose a novel
framework for evaluating























USA GAPPNET 2011 ACCE genomictechnology
4 step cycle:
(1) knowledge synthesis: aggregate
existing research and evidence using
explicit and reproducible methods to
identify, appraise, and synthesize
relevant studies;
(2) knowledge evaluation: seeks to
understand and measure accuracy,
reliability, validity and utility of genomic
based services,
(3) knowledge implementation: carrying
out plans for providing genomic-based
services,
(4) utilization: uptake and adoption of
new genomic-based services by
consumers and providers.







essential for the adoption of
genomic technologies into
practice




















-Economic and social implications
-Presentation
To develop an accessible set
of criteria that can provide






















































USA Not reported 2019 ACCE elective genomictesting
Analytical performance and interpretive
components
























Italy N/A 2019 ACCE genetic testing
1. Genetic tests:










-ethical, legal and social implications
patient perspective








framework that includes an
assessment of service
delivery






UK PHG Foundation 2007 ACCE Genetic Tests
1. evaluation of the assay
2. evaluation of clinical validity,
including clinical test performance
3. evaluation of clinical utility, including
test purpose (legitimacy, efficacy,
effectiveness, appropriateness), and the
feasibility of test delivery (acceptability,
efficiency, optimality, equity)
To propose an approach to
the evaluation of the
genetic tests that expand on






















6. Economic and Organisational Impact
The establishment of
frameworks and methods
to assess new genetic tests,
with the aim of defining the
services portfolio within






























5. Quality improvement program
6. Clinical utility





To develop a detailed
checklist on the evidence to
be produced to evaluate the









































Acceptable cut-offs for decisions
DOMAIN III:
Decisions under uncertainty
To develop an evaluation
model to guide public
coverage of new predictive
genetic tests in Ontario








































To provide an efficacy,
hierarchical model that





















Use of analytic frameworks
to specify the linkages and
key questions connecting
































NR literature review,expert panel Decision makers
Rapid ACCE







To present the rapid-ACCE
model and report our early
experience of using the
ACCE structure to guide
systematic reviews for the
rapid evaluation of
emerging genetic tests.
NR Expert panel Stakeholders,policymakers









































UK UK Genetic TestingNetwork (UKGTN) 2007 ACCE genetic tests
-laboratory details of the test
-test characteristics
-clinical details of the condition
-prevalence of the condition
-purpose of the test
-the healthcare context in which the test
is to be used
-the clinical utility of the test
-ethical, legal and social considerations
-the cost of the test
To evaluate genetic tests
and recommend which
tests will be provided by
the National Health Service




Int. J. Environ. Res. Public Health 2020, 17, 8001 9 of 21
2.5. Desk Research on the HTA Reports
In order to identify the HTA reports on omics technologies published by HTA agencies,
we conducted a desk research on the International Network of Agencies for Health Technology
Assessment [34] and on the NIHR Center for Reviews and Dissemination [35] websites. The search was
restricted only to publicly available reports published in English, Italian, German, Dutch, Portuguese,
Spanish and French until May 2020. The desk research on the HTA reports was performed by using
the key words “Genomic”, “Genome”, “Genetic”, “Proteomic”, “Metabolomics”, “Transcriptomic”,
“Testing”, “Assay”, “ and “Sequencing”.
3. Results
3.1. Search Results
The initial search of PubMed, Scopus, Web of Science and Embase identified a total number
of 6946 articles. After removing the duplicates, 3820 articles were screened by title and abstract.
One hundred and eight full-text articles were carefully read, of which nineteen articles met our inclusion
criteria. Eighty-nine were excluded for not describing a value assessment framework, considering
only one evaluation domain, or for not having a full text available. Four articles were included after
checking the reference lists of the evaluated full-texts. A total of twenty-three articles [11–33] were
included in the systematic review. The entire process of the study screening and selection process in
detail is shown in Figure 1.
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3.2. Characteristics of the Included Studies
The included twenty-three articles described twenty-two value assessment frameworks,
which covered the assessment of genetic and/or genomic technologies (Table 1). No frameworks
were identified for any other omics technology. The agencies working on these frameworks
were based mostly in USA (US Preventive Services Task Force, Centers for Disease Control and
Prevention, GAPNET, Cedar Associates LLC, Center for Comparative Effectiveness Research in
Cancer Genomics, IFCC Scientific Division Committee on Molecular Diagnostics and Advisory
Committee on Heritable Disorders in Newborns and Children), followed by Canada (Agency for
Healthcare Research and Quality, McMaster University, Agence d’évaluation des technologies et des
modes d’intervention en santé), UK (PHG Foundation, UK Genetic Testing Network), Spain (Junta
de Andalucia), Italy (Sapienza University) and EUnetHTA. Ten frameworks addressed genomics
testing and genome-based applications, eight frameworks addressed genetic testing, two addressed
general personalized medicine technology and one addressed newborn screening testing. Most of
the frameworks were derived from the “Analytic validity, Clinical validity, Clinical utility, Ethical,
legal and social implications” (ACCE) framework. The main categories of appraisal were clinical utility
(14 frameworks), clinical validity (10 frameworks), analytical validity (9 frameworks), and economic
evaluation (9 frameworks). Ethical, legal, and societal (ELSI) implications and organizational aspects
were considered in six and four frameworks, respectively. The frameworks were developed based
on an expert panel consultation (7/22), literature review and expert panel consultation (6/22), or only
literature review (4/22), and five articles did not report the methodological process.
3.3. Evaluation Frameworks
Fryback–Thornbury framework, published in 1991, is considered the first assessment framework.
This includes 24 items assessing technical efficiency of a test, diagnostic accuracy efficacy, diagnostic
thinking efficacy, therapeutic efficacy, patient outcome efficacy, and societal efficacy. Although this
framework has been considered as useful for certain types of screening and diagnostic tests, it has
been less useful for assessing genomic diagnostics [27]. The Centre for Disease Control and Prevention
(CDC) developed ACCE framework, which considers analytical validity, clinical validity, and utility,
and ELSI aspects of genetic and genomics testing [12]. The ACCE framework contains a list of 44 key
questions and could be considered the first consistently used framework for the assessment of genetic
tests. Although it was not the first published framework specifically created for genetic testing,
this framework was referenced the most often as the basis for more recently published frameworks
(Table 1). A rapid ACCE model has been developed with the aim to provide an evaluation in a
time frame that meets the decision needs and budgets of stakeholders [30]. This rapid framework,
which employs the same 44 key questions used in the original ACCE framework, involves a panel of
experts and independent reviewers and is most suitable for topics without a large evidence base [30].
Another framework deriving from the ACCE original framework is the PHG Foundation
framework [22], created specifically for the UK Genetic Testing Network (UKGTN). This framework
amends the ACCE framework in the following ways. Firstly, the PHG framework distinguishes
between the assay and the test. The assay is considered the method of determining the presence or
quantity of a certain component; therefore, the analytic validity is primarily the matter of the assay.
The genetic test relates to the assay but in a clinical situation, hence the context and the purpose of
the test is important. The assessment domains of clinical validity and clinical utility thus relates to
the genetic test. Secondly, the PHG framework distinguishes two concepts often conflated under
the banner of clinical validity—the link between genotype and disease and the evaluation of test
performance parameters. Thirdly, the incorporation of different aspects of healthcare quality into
the assessment of clinical utility, these include legitimacy, efficacy, effectiveness and appropriateness,
as stated by Donabedein et al. [36]. The framework was finally incorporated in the UKGTN gene
dossiers [32,33]. The gene dossier, developed by the UKGTN based on the ACCE model and the
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Canadian experience of genetic test evaluation, has evolved since its introduction in 2014 and provides
a standardized structure for the presentation of the essential information for genetic tests [32,33].
The ACCE framework was eventually updated by the Evaluation of Genomic Applications in
Practice and Prevention (EGAPP) working group [13]. The EGAPP working group, part of the CDC,
acknowledge that for genetic and genomic tests, a well-structured, standard of systematic evidence
review, such as the 44 questions of the ACCE framework, might not fit well for the assessment of these
tests. In addition to this, the working group also acknowledges that both the number and quality of
studies included in this domain are insufficient. The EGAPP framework therefore allowed for the
construction of a chain of evidence, effectively linking crucial elements of the evaluation together
through argumentation from analytical validity to clinical validity to finally clinical utility. The EGAPP
framework also incorporated some of the elements of the Fryback–Thornbury framework, such as
the impact of test utilization on decision-making. This framework provides specific methodological
guidance on hierarchies of evidence and considers the overarching question of the assessment to
be whether the genetic or genomic test shows clinical utility. From this main question, remaining
key questions are identified per assessment. The answers to these key questions are then used to
construct the chain of evidence, which finally answers the question of clinical utility. The framework
hence provides a more flexible approach to the assessment of genetic or genomic tests as compared
to its predecessor, the ACCE framework. This approach also allows for a quantitative assessment of
clinical utility through modelling of those genetic or genomic tests, which lack direct evidence [31].
The risk-benefit framework proposed by Veenstra et al. further developed this approach [11].
The novel aspect of this framework relies on the utilization of decision analytical modelling techniques
to model the effects of the genetic or genomic test, and the projection of several clinical outcomes,
such as quality-adjusted life-years. Another framework, LDT-SynFRAME, evaluates novel gene-based
laboratory developed tests, combining the most pertinent evaluation elements from other assessment
frameworks, mostly from ACCE. This new framework included the following components: a clear
introductory context, clinical utility, well-substantiated analytical and clinical validity, economic
outcomes, ethical aspects, and transparent presentation [18].
A priority-setting framework, derived from EGAPP, aimed to prioritize the assessment of
candidate genomic technologies in comparative effectiveness research trials. This new framework
identified the following nine original priority-setting criteria: health impacts, clinical benefits, economic
aspects, analytical and clinical validity, clinical trial implementation and feasibility, ethics and
recruitment, market factors and patient-reported outcomes [19].
The most recent framework, published in 2019, was based on ACCE and the non-genetic
test EUnetHTA core model® from Pitini and colleagues [21]. Along with the ACCE components,
it also considered economic evaluation, organizational aspect and delivery models. The latter was not
considered in other frameworks for the assessment practice of genetic and genomic tests. The EUnetHTA
HTA core model® is perhaps the most versatile and broadly accepted framework for the evaluation of
any technology; however, the model seems not well adapted for the evaluation of prognostic tests [15].
Other original frameworks are discussed above. An original framework called the “three-domain
model” was developed in Canada to guide technology assessment and decision-making with regards
to the emerging predictive genetic testing services [25]. The first domain covers evaluative criteria,
such as the purpose of the test, effectiveness, costs, demand and cost-effectiveness. The second
induces the acceptable cut-off point for each criteria, and the third addresses the need for guidance
for conditional coverage decisions. An innovative HTA framework (INESSS framework), developed
by Blancquaert et al. for genome-based health technologies, covers the assessment of the clinical
utility, analytical and clinical validity, acceptability of the screening and diagnostic strategies and the
interactions with healthcare services [26]. Another original framework called “The Genetic testing
Evidence Tracking Tool (GETT)” includes a list of 72 items that needs to be taken into account when
evaluating genetic testing implementation. In addition to the items of the ACCE framework, this tool
covers the availability of quality-control programs, laboratory and clinical guidelines, and the quality
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of the supporting data [24]. The Advisory Committee on Heritable Disorders in Newborns and
Children (ACHDNC) is an original analytic framework that evaluates the specificity of diagnostic and
screening tests, potential harms impact, health benefits and costs of diagnosis and treatment [29].
Among all the identified frameworks, ACCE, EGAPP, Fryback–Thornbury framework, EUnetHTA
core model and the USPSTF framework have already been piloted and applied in real evaluation
projects, considering the needs of patients, payers, regulators, and professional societies, as key
stakeholders [37,38].
3.4. HTA Reports
We identified forty-five HTA reports [39–83] conducted from agencies in 15 different countries,
mainly in Europe and Canada. The subjects of the assessment were predominantly the commercial
transcriptomic prognostics Mammaprint, OncotypeDx, Endopredict and Prosigna (48%), and the
genomic technology—next generation sequencing (22%). Based on the definition of HTA, the following
evaluation domains in the assessment reports were considered [9]: clinical effectiveness (38/45; 84%);
costs and economic evaluation (33/45; 73%); description and technical characteristics (31/45; 69%);
health problems (28/45; 62%); safety (49/45; 49%); organizational aspects (14/45; 31%); ethical analysis
(10/45; 22%) and social aspects (10/45; 15%). Although most of the HTA reports utilized the concepts
within the ACCE evaluation framework, only three reports referenced its use in the methodology
(Figure 2). Five reports mentioned EGAPP and only one report mentioned EUnetHTA HTA core model
(Supplementary Table S1).
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Figure 2. Characteristics of the available forty-five health technology assessment reports on
omics technologies.
4. Discussion
Our systematic review on value assessment frameworks for the evaluation of omics technologies
included twenty-three articles that reported twenty-two frameworks on genomics and genetic testing.
Most of these frameworks derived from ACCE, focusing on the analytical validity, clinical validity,
clinical utility and ELSI aspects. Over the course of recent years, new frameworks have been proposed
considering different aspects of the technology during its implementation process. These additional
elements cover the organizational aspect, health context, economic evaluation and delivery models.
The desk research in the HTA agencies repositories showed that a limited number of them report
the use of a value assessment framework in their practice for the evaluation of omics technologies.
The majority of these agencies were focused at the assessment of different domains of EUnetHTA HTA
core model and a few ACCE components.
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Our results indicate that the application of omics sciences in healthcare poses some particular
challenges to the HTA process. These challenges include familial implications from disseminating
omic information, the design of clinical trials to show clinical utility and the link between the
effectiveness of pharmaceuticals (e.g., precision medicines). Identifying these challenges is necessary
but not sufficient for decision-makers assessing whether to introduce new sequencing technologies
for genomic-based diagnosis. Therefore, further methodological work, supported by technical
developments in decision-analytic modeling, is needed [84].
The growth of omics technologies calls for an evaluation and assessment system that is accessible
to HTA professionals, managed-care payers, clinicians, and patients. The identified value assessment
frameworks may not meet all the required criteria during the evaluation process of omics technologies.
Although numerous omics technologies continue to emerge, to date, most of them have insufficient
evidence of clinical validity and utility for their use in clinical practice. The identified frameworks
concerned only genetic and genomic testing, probably because genomics are considered as the
predecessor of all other omics technologies and the most explored compared to the rest [1]. As of
2019, five transcriptomics assays and only one proteomic assay have ever been translated into clinical
practice, showing that translational outcomes are less advanced in other omics fields compared to
genomics. Most of the metabolomics studies focus on generating vast amount of data and developing
appropriate methods for metabolite measurements, which without an accurate validation decelerate
their translational capability in clinical practice [85]. However, the increased availability of more
quantitative data and proper validation methods might soon lead to the translations of proteins and
transcripts to clinical settings. Although metabolomics, proteomics and transcriptomics are emerging
omic technologies, once validated appropriately, they can be used by healthcare professionals as
diagnostic tools and also as a tool to assess therapeutic interventions for a more widespread impact on
the general population [86].
Despite being more explored, significant gaps exist in the evidence base of genomics, in terms
of efficacy, health outcomes, cost-effectiveness, and health services research [87]. Although several
frameworks have been proposed over the years to facilitate decision-making for the introduction
of genomics tests, some of them refer to tests in general, where others are too narrowly focused on
single-gene tests (e.g., screening) or in a particular clinical context (e.g., newborn screening).
These frameworks provide valuable insight into approaching the evaluation of genomic testing;
however, each have their limitations. There are important distinctions regarding analytical validity
and clinical validity for tests that contain an array of genes, or genes used in combination with other
predictors, including clinical factors or protein-based assays.
A single framework might be too general to apply to different clinical scenarios (e.g., screening,
diagnosis, prognosis or predictive testing). Considering this, EGAPP proposed different frameworks
for the following clinical settings: screening in asymptomatic populations for genetic susceptibility,
genetic screening for acquired disease, diagnostic testing for symptomatic disease, and genetic testing
to alter therapeutic approaches (e.g., pharmacogenetics) [13]. Furthermore, several of these frameworks
have been applied to real HTA evaluation projects, developing recommendations concerning clinical
applications and supporting the scientific evidence. The majority of the proposed frameworks derived
from ACCE, which is considered somewhat cumbersome, since it addresses 44 different questions.
However, ACCE, compared to the other frameworks, has been widely accepted for the evaluation of
genetic testing and is considered the basis for framework development. Although the framework was
not accredited for in the HTA assessments on omics technologies, the concepts established by ACCE
were commonly used throughout the assessments. From our research, cost-effectiveness and budget
impact analysis are considered the main decision-assisting tools to inform health policymakers how to
best allocate resources. Although the integration of omics technologies in the healthcare system poses
ethical issues regarding privacy, informed consent and data sharing, these aspects were not considered
in the retrieved reports as organizational and legal aspects, suggesting that these concerns have a small
influence in final HTA-related decision-making. Despite the availability of several tools to address
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ethical aspects in HTA, the lack of this consideration might be due to the difficulty of their application
and the subjectivity in ethical analysis [88,89]. Nevertheless, these aspects can, for example, determine
the clinical utility of a test and therefore can influence the effectiveness and cost-effectiveness as they
are context dependent. It should be therefore noted that the novel definition of HTA therefore explicitly
included these aspects: “These dimensions often include clinical effectiveness, safety, costs and
economic implications, ethical, social, cultural and legal issues, organizational and environmental
aspects, as well as wider implications for the patient, relatives, caregivers, and the population” [9].
The evaluations by HTA agencies on several omics technologies, of which Mammaprint and
OncotypeDx were amongst the most frequently assessed, show a repeated evaluation pattern over the
course of a decennia, considering that these tests were assessed by the National Institute for Health and
Care Excellence (NICE) in 2013 and later again in 2018 by Belgian Kenniscentrum Gezondheidszorg
(KCE), the Dutch Zorginstituut Nederland (ZIN)and the Canadian Agency for Drugs and Technologies
in Health (CADTH). This repeated assessment pattern illustrates the troublesome issue concerning
these diagnostics, the lack of direct evidence to establish their clinical utility and the difficulty in
obtaining these data. The practice of HTA agencies regarding omics technologies mainly consists
of clinical effectiveness and cost-effectiveness assessment. These domains are reported as the most
commonly evaluated in HTA reports of health technologies [90]. The lack of evidence on clinical utility
may cast uncertainty on these assessment domains.
Although clinical trials are undertaken to gather this evidence on these tests, healthcare payers
have also launched their own initiatives to start covering the tests under a coverage with evidence
development (CED) program, thus the future role of real world data and its analysis to produce real
world evidence should be carefully considered [4,5,91–93]. Evidence is thus continuously gathered,
either through clinical trials or through CED programs, which inform later re-assessments of these
technologies in their life cycle. This continuous evaluation along the test life cycle should also be
considered in value assessment frameworks. With CED programs and early dialogue and early advice
between HTA agencies and manufacturers becoming more prominent, HTA agencies’ role is partially
shifting from passive evaluators to co-creators of a technology. Value assessment frameworks should
therefore reflect this shifting role and also consider the question of whether they are interacting in the
life cycle of the omics technology.
The present work, as with any other systematic review, has the potential of publication bias as we
included only articles published in English. In order to minimize this, we conducted a rigorous search
in the reference list of the evaluated full texts. We were not able to assess the quality of the included
articles; however, we evaluated the methodological approach, which showed that the majority of the
frameworks were developed based on a specific methodology, such as literature reviews and panel
expert consultations. To our knowledge, this is the first attempt concerning the identification of HTA
evaluation frameworks for omics sciences, and addressing the practical use of these frameworks by
HTA agencies.
Not all the aspects were addressed explicitly among the identified frameworks, which may
generate the necessity to create a generalized comprehensive framework, which may result in some
challenges due to the heterogeneity of genetic conditions. The rapid advancement of these technologies
indicates the need for a continued and regular update of a framework for assessing molecular classifiers.
5. Conclusions
We identified twenty-three value assessment frameworks, mostly in the domain of genetic and
genomic testing, which could potentially be used for the assessment of omics technologies. However,
hardly any frameworks were used for the assessment in the reports produced by HTA agencies.
In these reports, the most assessed criteria were clinical effectiveness and cost-effectiveness. A value
assessment framework for the HTA evaluation of omics technologies is not standardized and accepted
yet. Our work identified the most evaluated domains as analytical validity, clinical validity, clinical
utility and economic aspects. Technical description, organizational characteristics and ELSI aspects are
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not often considered for omics technologies, despite the importance of them due to the consequences
of managing omics information not just for the individual person but also relatives.
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